Trials / Active Not Recruiting
Active Not RecruitingNCT06022250
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK),Pharmacodynamic characteristics, immunogenicity and antitumor activity of JS207 in patients with advanced malignant tumor. The Recommended dose for phase II trial （RP2D） will be determined based on the safety, tolerability, pharmacokinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JS207 | Patients will receive specific dose of JS207 via intravenous infusion. |
Timeline
- Start date
- 2023-09-26
- Primary completion
- 2025-12-31
- Completion
- 2026-06-30
- First posted
- 2023-09-01
- Last updated
- 2025-09-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06022250. Inclusion in this directory is not an endorsement.